Generic Name and Formulations:
Methsuximide 150mg, 300mg; caps.
Indications for CELONTIN:
Absence (petit mal) seizures refractory to other drugs.
Adults and Children:
Individualize. Initially 300mg once daily for the 1st week; if needed, may increase at weekly intervals by 300mg/day for 3 weeks based on response; max 1.2g daily. May be administered with other anticonvulsants.
Perform blood counts periodically, esp. if signs/symptoms of infection develop. Hepatic or renal impairment. Monitor urine and liver function tests. Systemic lupus erythematosus. Suicidal ideation. Monitor for worsening of depression, suicidal thoughts and/or unusual changes in behavior. Change dose gradually. Avoid abrupt cessation. May increase frequency of grand mal seizures when used alone. Pregnancy.
May potentiate phenytoin, phenobarbital; monitor periodically.
Nausea, vomiting, diarrhea, weight loss, abdominal pain, constipation, blood dyscrasias, confusion, depression, drowsiness, ataxia, dizziness, Stevens-Johnson syndrome, urticaria, hyperemia, proteinuria, hematuria, periorbital edema; rare: psychosis.